BAY3546828 clinical trials

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

This study is testing a new treatment, BAY3546828, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to find a safe and effective dose, understand how it works in the body, and see if it can shrink tumours.